Business NewsPR NewsWire • Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676

Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676

Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676

MONROVIA, Calif., June 28, 2016 /PRNewswire/ -- Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb®14045 expected to begin clinical...

View More : http://www.prnewswire.com/news-releases/xencor-announces-strategic-collaboration-for-bispecific-programs-including-xmab-...
Releted News by prnewswire
Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676
Ergebnisse des 20. Internationalen Wirtschaftsforums in St. Petersburg: Von der neuen, weltweiten wirtschaftlichen Realität profitieren
Resultados de la 20 edición del Foro Económico Internacional de San Petersburgo